Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) reported its financial results on Wednesday for the second quarter of fiscal 2022, revealing a 4% year-over-year increase in revenue to $218 million.
The transaction with Columbia Care Inc. (OTCQX:CCHWF) (NEO:CCHW) (CSE:CCHW) (FSE: 3LP) is proceeding as expected,” Charles Bachtell, the company’s CEO and co-founder, said in a press release adding that “the divestiture and regulatory processes are on track and we continue to anticipate a closing around year-end.”
